Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the formation of a Scientific Advisory Board (SAB) for its radiopharmaceuticals, chaired by Prof. Ken Herrmann, M.D., a globally renowned expert in the field of nuclear medicine with more than two decades of experience.

“Molecular Partners’ Radio-DARPins have the potential to unlock targeted radiopharmaceuticals against a broad spectrum of tumor targets. These represent ideal vectors to precisely deliver potent alpha-emitting isotopes in cancer patients. In particular, I am excited by the first human images of MP0712 presented last month and look forward to phase 1 initiation. I am honored to Chair this Scientific Advisory Board and to collaborate with this esteemed group of experts, as we work to develop therapies that can redefine patient care,” said Ken Herrmann, M.D., Chair of the Molecular Partners SAB.

“The precision radiopharmaceuticals being developed from our Radio-DARPin platform are showing considerable promise, including encouraging early clinical signs from our lead Radio-DARPin candidate MP0712. Ken Herrmann’s expertise in nuclear medicine and his vision for the field make him the ideal leader for our Scientific Advisory Board, where he will be joined by a group of distinguished experts. This group will guide our transition from early clinical validation to strategic clinical development decisions that realize the full potential of our platform. Together, we aim to accelerate the development of our Radio-DARPin candidates and bring improved treatment options to patients in need,” said Patrick Amstutz, Ph.D., CEO of Molecular Partners.

Ken Herrmann is Chair of the Department of Nuclear Medicine at University Hospital Essen, Germany, and a globally recognized expert in theranostics and nuclear medicine, with extensive experience in clinical development and translational research. He previously acted as Adjunct Professor at the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA), California, USA, and served as Chair of the European Association of Nuclear Medicine (EANM) Oncology & Theranostics Committee. Ken Herrmann completed his residency in nuclear medicine at the Technische Universität München, Germany, and holds an executive MBA from the University of Zürich, Switzerland.

Ken Herrmann’s leadership will be instrumental in shaping Molecular Partners’ strategic direction, particularly as the company transitions from early clinical validation to pivotal development decisions.

The SAB also includes:

• radiopharmaceutical industry executive James Cook, previously founder and CEO of Evergreen Theragnostics (sold to Lantheus in 2025) and U.S. Chief Operating Officer at Advanced Accelerator Applications (acquired by Novartis in 2017), where his team commercially launched Lutathera and Netspot;
• radiochemist Prof. Jason Lewis, Ph.D., the Emily Tow Chair in Oncology at Memorial Sloan Kettering Cancer Center and a Deputy Director of the Sloan Kettering Institute (SKI); and
• medical oncologist and nuclear medicine specialist Prof. Michael Morris, M.D., Steven A. Greenberg Chair in Prostate Cancer Research and Prostate Cancer Section Head at the Memorial Sloan Kettering Cancer Center.

The SAB will provide critical input on candidate development and guiding the transition from early clinical validation to late-stage trials, on platform expansion, such as exploring additional isotopes and novel targeting mechanisms, and cross-disciplinary innovation, leveraging the members’ diverse expertise to refine and challenge the company’s scientific and clinical strategies.

Molecular Partners’ Radio-DARPins represent ideal vectors for efficient delivery of potent alpha-emitting isotopes to tumor lesions and have the potential to unlock targeted radiopharmaceuticals across a broad range of tumor targets. The Company’s lead program MP0712 is a ²¹²Pb-based Radio-DARPin candidate targeting DLL3 for the treatment of small cell lung cancer and other neuroendocrine cancers, co-developed with strategic partner Orano Med. The second RDT program slated for clinical development is MP0726, targeting mesothelin (MSLN), a tumor target overexpressed across several cancers with high unmet need, such as ovarian cancer. The Company’s proprietary technology continues to produce promising Radio-DARPins against new targets, addressing the key challenges of targeted radiotherapy by balancing precise delivery of a potent radioactive payload to the tumor while sparing healthy tissues.